Inventor · disambiguated record
Lars Toleikis
Also filed as: TOLEIKIS LARS
7 granted patents·11 pending applications·15 citations·filing 2009–2024
78Inventor score
Top patents by PatentIndex Score
18 records- 0183US12129308B2MMP13 binding immunoglobulinsMERCK PATENT GMBH·Filed 2018·Granted Oct 29, 2024·2 cites·16 claims
- 0278US8969318B2Bispecific aptamers mediating tumour cell lysisTOLEIKIS LARS·Filed 2011·Granted Mar 3, 2015·7 cites·8 claims
- 0377US11813307B2Polypeptides binding ADAMTS5, MMP13 and aggrecanMERCK PATENT GMBH·Filed 2018·Granted Nov 14, 2023·2 cites·13 claims
- 0476US11603401B2Aggrecan binding immunoglobulinsABLYNX NV·Filed 2018·Granted Mar 14, 2023·2 cites·13 claims
- 0576US2025129183A1Mmp13 binding immunoglobulinsMERCK PATENT GMBH·Filed 2024·Application pending·0 cites
- 0673US9546217B2Recombinant anti-MUC1 antibodiesBEHRENS CHRISTIAN·Filed 2009·Granted Jan 17, 2017·2 cites·15 claims
- 0769US2024181006A1Polypeptides binding adamts5, mmp13 and aggrecanMERCK PATENT GMBH·Filed 2023·Application pending·0 cites
- 0866US2025179210A1Anti-ceacam5 antibodies and conjugates and uses thereofMERCK PATENT GMBH·Filed 2023·Application pending·0 cites
- 0965US2023312694A1Aggrecan binding immunoglobulinsABLYNX NV·Filed 2022·Application pending·0 cites
- 1060US2024343800A1Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokinesMERCK PATENT GMBH·Filed 2024·Application pending·0 cites
- 1158US2022111064A1Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereofMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 1252US2023310629A1Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereofMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 1351US2024287177A1Vhh-based nkp30 bindersMERCK PATENT GMBH·Filed 2022·Application pending·0 cites
- 1450US11235063B2Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereofMERCK PATENT GMBH·Filed 2016·Granted Feb 1, 2022·0 cites·28 claims
- 1550US2025122282A2Anti-ceacam5 antibodies and conjugates and uses thereofMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 1646US11597771B2Monoclonal antibody directed to FGFR1MERCK PATENT GMBH·Filed 2017·Granted Mar 7, 2023·0 cites·15 claims
- 1744US2023287082A1Nkp30 bindersMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 1831US2019248907A1Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibitionMERCK PATENT GMBH·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lars Toleikis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →